Carl Dambkowski Sells Shares of ORKA $ORKA
Key Points
- Carl Dambkowski sold 12,583 shares of Oruka Therapeutics, Inc. ($ORKA) worth $882,194.
- $ORKA last traded around $68.47.
Carl Dambkowski, insider at Oruka Therapeutics, Inc. ($ORKA), sold 12,583 shares at an average price of $70.11, for a total transaction of $882,194. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oruka Therapeutics, Inc. ($ORKA) Stock
Oruka Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.